957 results about "Aspirin" patented technology

A liquid composition applied transdermally for relief of pain comprising alcohol in an amount by weight of about 57 to about 91 percent; glycerin in an amount by weight of about 1 to about 12 percent; an analgesic agent in an amount by weight of about 2 to about 28 percent, the analgesic agent comprising a derivative of salicylic acid; methylsulfonylmethane in an amount by weight of about 0.02 to 5 percent; and emu oil in an amount by weight of about 0.01 to 3 percent, the liquid composition permeating skin to relieve pain. The composition further comprising, as an additional feature, aloe vera in an amount by weight of at least about 0.05 percent and having an amount by weight of about 0.05 to 4 percent. The composition features transdermal pain relief such that a patient can apply the analgesic agent directly to an area of pain without such side effects as stomach irritation which is normally associated with aspirin. The composition may be sprayed or rolled directly onto the painful area. Because of the unique formula, the composition is safe to vital internal organs, requires no mixing before use, and is shelf stable for marketing purposes.

A bottle cap is adapted to retain a quantity of an additive, such as for example aspirin or the like. The additive is retained in an isolated condition within a sealed chamber or within a bladder inside the bottle cap but in fluid communication with the liquid within the bottle, such as water. Means are provided to breech the seal of the chamber or the bladder, thereby releasing some or all of the additive retained within the bottle cap.

A method for delivering ultrasound energy to a patient's intracranial space includes the steps of forming a hole in a patient's skull, locating an ultrasound transmitter near or into the hole, and transmitting ultrasound from the transmitter into the intracranial space, wherein the Mechanical Index of ultrasound energy traveling through cerebral tissue in the intracranial space is less than 1.0, the power intensity delivered to a target tissue in the intracranial space is greater than 50 mW / cm2 and less than 200 mW / cm2, and the frequency of the transmitted ultrasound is within the range between 500 kHz and 2 MHz. Microbubbles, aspirin, both microbubbles and aspirin, and a mixture of microbubbles and aspirin, can also be delivered into the intracranial space.

A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphinic acid, phosphonic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, 0-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.

A bottle cap is adapted to retain a quantity of an additive, such as for example aspirin or the like. The additive is retained in an isolated condition within a sealed chamber or within a bladder inside the bottle cap but in fluid communication with the liquid within the bottle, such as water. A cap with at least one downward extending protrusion is provided to breech the seal of the chamber or the bladder, thereby releasing some or all of the additive retained within the bottle cap.

The present invention relates to the compositions that enhance post-exercise recovery processes to increase both strength and muscle mass, replace glycogen stores, and prevent inflammation, resulting in the prevention and / or reduction of delayed onset muscle soreness. Additionally, it provides a feeling of muscle relaxation as well as a feeling of mental tranquility immediately following exercise. The composition consists of any or all high-glycemic sugars and / or polysaccharides (e.g., sucrose, glucose, maltodextrin), all essential amino acids and beta-hydroxy-beta-methylbutyrate and can include other amino acids sources (e.g. whey protein), performance enhancing agents (e.g., caffeine, L-glutamate), anti-inflammatory agents (e.g., ginger, boswellia, curcumen), antioxidants (vitamin C, vitamin E, selenium, polyphenols,), insulin-mimicking agents (cinnamon, Banaba), analgesics (e.g. aspirin, ibuprofen, naproxen, acetaminophen), and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof.

Mixtures, such as gels or pastes, comprising freeze-milled cartilage particles and exogenous growth factors are used for repairing chondral defects. Such mixtures may be applied to constructs comprising cancellous bone for implantation at the defect site. Suitable growth factors include variants of FGF-2, particularly variants that include a sole amino acid substitution for asparagine at amino acid 111 of the β8-β9 loop of the FGF-2 peptide. Such FGF-2 variants are released slowly and continuously at a constant rate from cartilage pastes. In other embodiments, the amino acid substituted for asparigine is glycine. Other variants that may be used include FGF-9 variants having truncated chains and a sole amino acid substitution in the β8-β9 loop of the FGF-9 peptide either for tryptophan at amino acid 144 or for asparagine at amino acid 143.

The present invention provides a therapeutic method for treating gastric lesions, including administration to a patient in need thereof of an effective amount of an A2A adenosine receptor agonist. The A2A adenosine receptor agonist can be a compound of formula (I) as disclosed herein. The invention further provides a therapeutic method for treating the patient with an A2A adenosine receptor agonist, optionally, in combination with a Type IV phosphodiesterase (PDE) inhibitor. In one embodiment, the gastric lesions are caused by, or aggravated by, the use of NSAIDS such as, for example, aspirin.

Compounds comprising multi-vitamins, zinc and an anti-platelet aggregating agent for the treatment of atherosclerotic cardiovascular disease (ASCVD) are disclosed. The compounds are provided in dosage form, and preferably include selected amounts of ascorbic acid, folic acid, vitamin E, vitamin B6 and vitamin B12. The anti-platelet aggregating agent preferably comprises aspirin. A protective coating is preferably provided between the aspirin and the other vitamin and mineral constituents. The dosages are effective in the treatment of ASCVD, and possess extended shelf lives.

In one aspect, the present invention provides a composition of a covalent conjugate of an eflornithine analog with an anti-inflammatory drug. In another aspect, the present invention provides a composition of an eflornithine prodrug. In another aspect, the present invention provides a composition of an eflornithine or its derivatives aspirin salt. In another aspect, the present invention provides methods for treating or preventing cancer using the conjugates or salts of eflornithine analogs or eflornithine prodrugs.

A method for delivering ultrasound energy to a patient's intracranial space includes the steps of forming a hole in a patient's skull, locating an ultrasound transmitter near or into the hole, and transmitting ultrasound from the transmitter into the intracranial space, wherein the Mechanical Index of ultrasound energy traveling through cerebral tissue in the intracranial space is less than 1.0, the power intensity delivered to a target tissue in the intracranial space is greater than 50 mW / cm2 and less than 200 mW / cm2, and the frequency of the transmitted ultrasound is within the range between 500 kHz and 2 MHz. Microbubbles, aspirin, both microbubbles and aspirin, and a mixture of microbubbles and aspirin, can also be delivered into the intracranial space.

The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases.The invention also encompasses certain pharmaceutical compositions and methods for treating cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I. The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while also reducing the risk of thrombotic cardiovascular events.

The invention relates to a dual-emission ratio-type quantum dot fluorescence probe for visual detection of aspirin, a preparation method and an application thereof and belongs to the technical field of preparation of material and detection of content of medicines. The preparation method of the probe includes following steps: preparing a precursor NaHTe solution from sodium borohydride, tellurium powder and water under an ultrasonic environment; adding the precursor to an aqueous solution of CdCl2.2.5H2O in the presence of thioglycollic acid; carrying out a reflux reaction with a nitrogen protecting condition to obtain required green fluorescence quantum dot and red fluorescence quantum dot; by means of a sol-gel method, wrapping the red fluorescence quantum dot with silicon spheres with amino group being connected; dispersing a green fluorescence quantum dot solution and the red fluorescence quantum dot wrapped with the silicon spheres in an MES buffer solution with addition of an EDC / NHS solution; and carrying out a reaction at room temperature in a dark place to obtain the dual-emission ratio-type quantum dot fluorescence probe. The dual-emission ratio-type quantum dot fluorescence probe is used in detection of the content of the aspirin through fluorescence quantitation and visualized analysis. The quantum dot fluorescence probe is quite good in optical performance and stability and has a capability of visualizedly detecting the aspirin.

A water-soluble aspirin-theanine cocrystal composition which includes a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer associated with the quantity of acetylsalicylic acid. The composition may be created by a method including the steps of: (i) providing a quantity of acetylsalicylic acid; (ii) adding a quantity of a theanine enantiomer to the quantity of acetylsalicylic acid to form a mixture comprising the quantity of acetylsalicylic acid and the enantiomer of theanine; (iii) wetting the mixture; and (iv) grinding the mixture for a length of time sufficient to produce a dried crystalline mass. The water-soluble cocrystal composition is suitable for intravenous administration, preferably to humans.

The present invention is generally drawn to novel isolated therapeutic agents, termed lipoxins, generated from the interaction between a dietary omega-6 polyunsaturated fatty acid (PUFA) such as arachidonic acid (AA), oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of AA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of AA (lipoxins, aspirin-triggered epi-lipoxins) that diminish, prevent, or eliminate NV, hemangiogenesis and / or angiogenic condition(s) of corneal tissue. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.

The invention discloses a plant rooting aid. The plant rooting aid comprises the following components in percentage by weight: 36.44% of distilled water, 1% of rice vinegar, 0.05% of aspirin, 12% of vitamin B12, 10% of cane sugar, 20% of honey, 20% of a withy leaching agent, 0.5% of potassium permanganate and 0.01% of acetic acid. Compared with the prior art, The plant rooting aid is mostly prepared from natural materials, low in cost, very low in content of chemical agents, capable of strengthening nutrition of plants and promoting the rooting of the plants and has popularization and application values.

Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and / or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and / or known anti-inflammatory drugs, such as aspirin.

Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and / or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and / or known anti-inflammatory drugs, such as aspirin.

An auxiliary container (10) adapted for unintrusive coupling with a conventional medication container (12), such as pill bottle, cream tube, or spray can, wherein the auxiliary container (10) provides an independent storage space (26) which does not require breaking a seal of, removing, or replacing an existing lid (70) or cap of the conventional container (12). In one contemplated use, for example, the auxiliary container (10) is used to store small doses of a supplementary medication (14), such as aspirin, in close association with a primary medication (e.g., a heart medicine such as nitroglycerine), such that both are conveniently available and accessible for immediate use. In a preferred first embodiment, the auxiliary container (10) broadly comprises a body (16); a lid (18); a closure mechanism (20); and a coupling mechanism (22).

A technique for assuring patient use of the correct drug pill for a prescribed treatment of a particular body organ or part, involving shaping the pill to have an appearance resembling such body organ—in particular, appropriate prophylactic-dose aspirin pills of heart-shape, as well as other drug pills for treating other body parts the shape of which is imparted to the respective pills.

A method for the prevention of diseases caused by thrombus or embolus. The method is to separately administer 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, in their pharmacologically effective amounts, to a warm-blooded animal.

The invention relates to a ursolic acid-aspirin conjugate shown in a formula (I) and application thereof in preparing drugs for preventing tumor metastasis. In vivo experiments verify that the ursolic acid-aspirin conjugate provided by the invention has a remarkable inhibitory effect on adhesion, migration, invasion and the like of tumor cells. in vivo animal experiments verify that the ursolic acid-aspirin conjugate can be used for reducing experimental pulmonary metastasis of 4T1 breast cancer of a rat and showing a relatively good tumor metastasis resisting effect. The ursolic acid-aspirin conjugate provided by the invention can be applied to preventive drugs for tumor metastasis, thereby providing novel selection for developing new drugs for tumor metastasis and preventing postoperative retransfer of malignant tumors. The formula (I) is shown in the description.

The present invention relates to methods and compositions for identifying and treating subjects in need of antithrombotic therapies but who are not responsive to aspirin.

Use of a high shear mechanical device in a process for production of acetyl salicylic acid, by contacting acetic anhydride with salicylic acid in a high shear device. The disclosed process makes possible a decrease in mass transfer limitations, thereby enhancing production of acetyl salicylic acid. A system for production of acetyl salicylic acid is also provided in which a reactor is configured to receive the output from a high shear device, which is configured to receive, via one or more inlets, acetic anhydride, and salicylic acid and generate a fine dispersion or emulsion of reactants.

The invention provides a method for preparing a tiny mesoporous silica drug sustained-release material and a tiny mesoporous hollow tubular silicon dioxide material obtained through the method. The drug loading capacity, calculated through a TG method, of the tiny mesoporous hollow tubular silicon dioxide material for aspirin model drugs is 15%, the sustained-release stage is the time of six hours of the initial stage of an experiment, and the drug releasing rate is high; after six hours, the stage of release balancing is achieved, and the amount of balanced release is 73.6%.

A method for assessing aspirin resistance and relative risk of a cardiovascular event in a patient taking aspirin is provided. The concentration of 11-dehydro-thromboxane B2 in a urine sample is measured and compared to a set of standardized quartile concentrations. A concentration of urinary 11-dehydro-thromboxane B2 that falls within the second, third, or fourth quartile is indicative of aspirin resistance and an elevated risk of a recurrent cardiovascular event.

A tablet with an enhanced dissolution profile for a medicinally active ingredient such as aspirin and methods for making the tablet. The tablet comprises a blend of crystals of the medicinally active ingredient and a dissolution aid such as sodium or calcium carbonate or bicarbonate that coats the crystals upon co-milling. The blend is then compressed to form tablets that have an enhanced dissolution profile for the medicinally active ingredient.

The invention discloses an aspirin enteric-coated pellet which comprises the following components in percentage by weight from inside to outside: 5-22 blank core pellet, 55-75 medicinal layer consisting of aspirin and medicinal excipients and 20-35 enteric-coated layer. The invention also discloses a method for preparing the aspirin enteric-coated pellet and an aspirin enteric-coated capsule containing the aspirin enteric-coated pellets. The aspirin enteric-coated capsule has the advantages of good stability, small stimulation, steady blood concentration, high bioavailability, and the like.

The present invention provides a new type balloon dilation catheter which includes ballon and medication material coated on stent. Said medication material comes from one or two and more than two mixtures of heparin sodium, fiber degrading enzyme, serine proteinase, batroxobin, aspirin, genistein, hirudin and its recombined product, colchicine, sirolimus, biolimus, zotarolimus, tracrolimus, pimecrolimus, simvastatin, atorvastatin, pravastatin, ciclosporin, Anti-CD34, dexamethasone, bleomycin, plicamycin, daunomycin, mitomycin C, actinomycin D, taxol, celastrol, methopterin, 5-fluorouracil, cytarabine and 6-purinethol. The balloon is made of macromolecule nylon material, and the stimulation to blood vessel is far lower than the stent with metal structure.